experimental peptide drug derived vasoactive intestinal peptide vip change behavior immune cells protect dopamineproducing cells rather attacking drug studied potential use parkinsons specifically targets receptor unlike drug also affects addition durable body compared scientists university nebraska medical center longevity biotech inc first demonstrated use drug mouse phase trial humans planned still preclinical development